Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences 7-11-2024, 19:05

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Constellation Brands Issues 2023 ESG Impact Report and Announces Enhanced Water Withdrawal Restoration Target Benefitting Local Communities 24-10-2023, 20:00